Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

Trastuzumab (Herceptin) is a humanized IgG(1) kappa monoclonal antibody, specifically targeted against the extracellular domain of the human epidermal growth factor receptor 2 (HER2), and is indicated for the treatment of HER2-positive early or metastatic breast cancer. This review discusses the available data regarding its use in early breast cancer. Trastuzumab, when administered concurrently with chemotherapy regimens, consistently prolonged disease-free survival (primary endpoint) and overall survival (secondary endpoint) in patients with HER2-positive early breast cancer in well designed trials; studies evaluating sequential trastuzumab treatment have produced mixed results for these endpoints. Further study is required to ascertain the optimal trastuzumab treatment regimen, including the duration of treatment. Trastuzumab was generally well tolerated when added to, or administered following, a chemotherapy regimen in clinical trials. While cardiac adverse events, such as a decreased left ventricular ejection fraction and congestive heart failure, are a concern, these effects are treatable and appear to be mostly reversible. Thus, trastuzumab is a valuable component of treatment regimens for HER2-positive early breast cancer.

[1]  C. Chant,et al.  Early and locally Advanced Breast cancer , 2022 .

[2]  Scott D. Ramsey,et al.  The Costs of Treating Breast Cancer in the US , 2012, PharmacoEconomics.

[3]  J. Thigpen.  Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial , 2010 .

[4]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[5]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[6]  Andre T Baron,et al.  Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. , 2009, Cancer research.

[7]  M. Ellis,et al.  Synergistic Interactions Between Tamoxifen and Trastuzumab (Herceptin) , 2005 .

[8]  Jorma Isola,et al.  Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[10]  K. Carraway,et al.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.

[11]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[12]  K. Ang,et al.  Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.

[13]  S. Keam,et al.  Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer , 2012, BioDrugs.

[14]  A. Wardley,et al.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring , 2009, British Journal of Cancer.

[15]  Yi Shen,et al.  Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer , 2009, Molecular Cancer Therapeutics.

[16]  E. Perez,et al.  Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. , 2009 .

[17]  Andreas Makris,et al.  Early breast cancer , 2009, The Lancet.

[18]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[19]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[20]  M. Pollak,et al.  Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells , 2004, International journal of cancer.

[21]  S. Hilsenbeck,et al.  Neoadjuvant trastuzumab induces apoptosis in primary breast cancers , 2005, Nature Clinical Practice Oncology.

[22]  J. Schueller,et al.  Pharmacokinetics of Gemcitabine Combined with Trastuzumab in Patients with Advanced Breast Cancer , 2005, Oncology Research and Treatment.

[23]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[24]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[26]  K. Fujimoto-Ouchi,et al.  Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models , 2002, Cancer Chemotherapy and Pharmacology.

[27]  C. Bamdad,et al.  MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells , 2009, Breast Cancer Research and Treatment.

[28]  E. Perez,et al.  Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .

[29]  C. Perry,et al.  Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer. , 2007, Drugs.

[30]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Seema A Khan,et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[33]  R. Gelber,et al.  Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  A. Kurian,et al.  A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Mackey,et al.  Adjuvant trastuzumab: progress, controversies, and the steps ahead , 2006, Current oncology.

[37]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[38]  P. Klein,et al.  Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.

[39]  S. Ropero,et al.  Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma , 2004, Breast Cancer Research and Treatment.

[40]  M. Fehr,et al.  Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  K. Lyseng-Williamson,et al.  Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. , 2008, PharmacoEconomics.

[42]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[43]  J. Baselga,et al.  Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis , 2007 .

[44]  L. Crinò,et al.  Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). , 2008, Clinical breast cancer.

[45]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[46]  C. Perry,et al.  Trastuzumab , 2002, Drugs.

[47]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[48]  H. Lane,et al.  Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[50]  C. Tacchetti,et al.  TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. , 2005, Oncogene.

[51]  E. Shpall,et al.  Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer , 2004, Clinical Cancer Research.

[52]  Mitch Dowsett,et al.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[54]  M. Venturini,et al.  Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[56]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  L. Carey,et al.  Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. , 2010, International journal of radiation oncology, biology, physics.

[58]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[59]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[60]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[61]  Naoto T Ueno,et al.  P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. , 2004, Cancer research.

[62]  E. Winer,et al.  Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Bergh,et al.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[65]  K. Gelmon,et al.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[67]  M. Neyt,et al.  Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. , 2008, Health policy.

[68]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[69]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.